Janelidze, Shorena <br/><br/>
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.  [electronic resource] 

 -  Nature communications  04 2020 
 - 1683 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-020-15436-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Alzheimer Disease--cerebrospinal fluid<br/>Biomarkers--cerebrospinal fluid<br/>Brain--diagnostic imaging<br/>Carbolines--administration & dosage<br/>Contrast Media--administration & dosage<br/>Diagnosis, Differential<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Phosphorylation<br/>Positron-Emission Tomography<br/>Sweden<br/>tau Proteins--cerebrospinal fluid